These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36597217)

  • 1. Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric β-Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study.
    Hong X; Chen Y; Lu J; Lu Q
    Pediatr Transplant; 2023 Mar; 27(2):e14466. PubMed ID: 36597217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
    Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
    Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation].
    Chen YM; Hong XL; Lin JZ; Shi J; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1586-1589. PubMed ID: 36208270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
    Lebon D; Dujardin A; Caulier A; Joris M; Charbonnier A; Gruson B; Quint M; Castelain S; François C; Lacassagne MN; Guillaume N; Marolleau JP; Morel P
    Leuk Res; 2023 Feb; 125():107005. PubMed ID: 36580876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia.
    Zhumatayev S; Yalcin K; Celen SS; Karaman I; Daloglu H; Ozturkmen S; Uygun V; Karasu G; Yesilipek A
    Pediatr Transplant; 2024 Feb; 28(1):e14688. PubMed ID: 38317344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
    Khandelwal P; Yeh RF; Yu L; Lane A; Dandoy CE; El-Bietar J; Davies SM; Grimley MS
    Transplantation; 2021 Apr; 105(4):891-896. PubMed ID: 32467478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of EB virus infection between short term and long term use of mycophenolate mofetil for prophylaxis of graft versus host disease after haploidentical hematopoietic stem cell transplantation].
    Yu CZ; Huang XJ; Xu LP; Liu KY; Zhang XH; Sun YQ; Liu JY; Zhao XY; Wang Y
    Zhonghua Nei Ke Za Zhi; 2021 Sep; 60(9):806-811. PubMed ID: 34445816
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute Graft versus Host Disease in Beta Thalassemia Patients Following Allogeneic Haematopoietic Stem Cell Transplantation.
    Rafique N; Ali A; Ghaffor T; Khattak TA; Asghar MB; Chaudhry QU
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):480-483. PubMed ID: 38576294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases].
    Li XP; Li Y; Liu L; Yuan ZT; Wang YC; Dong YC; Zhang DS; Feng J; Chen YN; Wang SB
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):128-133. PubMed ID: 38604788
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major.
    Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
    Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
    Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.
    Luo YH; Yang J; Wei A; Zhu GH; Wang B; Zhang R; Jia CG; Yan Y; Wang K; Li S; Zhou X; Qin MQ; Wang TY
    World J Pediatr; 2021 Dec; 17(6):626-636. PubMed ID: 34739695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
    Medina D; Estacio M; Rosales M; Manzi E
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):208-213. PubMed ID: 32224144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
    Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
    Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
    Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
    Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.